Pak1 Pathway Hyper-Activation Mediates Resistance to Endocrine Therapy and CDK4/6 Inhibitors in ER+ Breast Cancer

Researchers generated two estrogen receptor (ER) + breast cancer cell lines, T47D and MCF7, resistant to the combination of the ER antagonist fulvestrant and CDK4/6i abemaciclib, named T47D-FAR and MCF7-FAR.